After Novo Nordisk breached not one, not two, but seven clauses of the code that regulates U.K. drugmakers, its U.K. general manager is stepping down as president of the industry's national ...

The pharmaceutical industry’s offer includes an annual £1bn boost to the NHS as well as an additional £1bn new investment facility to maximise the potential of the UK’s health and life science ...

Delivering a shared agenda for the UK’, it explored how to ensure NHS patients benefit from the latest medicines and vaccines ...

Amanda Callaghan has decided to leave the ABPI after nearly two years as director of corporate affairs. Amanda said: “After nearly two years at the ABPI I have decided that it’s time for me to move on ...

Five vital new appointments made to regulator’s insight, perspective and advice group Five vital new appointments made to regulator’s insight, perspective and advice group The Association of the ...

The pharmaceutical company had previously been subjected to a 2-year suspension. The Association of the British Pharmaceutical Industry (ABPI) reinstated Novo Nordisk’s membership in the group. 1 The ...

While there are tremendous challenges facing the UK health system, the innovative pharmaceutical industry is ready to be an active partner in helping to fix the broken NHS. The Darzi Review makes ...

Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time. The document from the Prescription ...

Elliot Dunster (pictured) will start in his new role as executive director of comms at the IFPMA in April. He will manage three members of staff and report to director-general Thomas Cueni. Dunster ...

The more healthcare professionals (HCPs) know the pharma industry, the more they trust the pharma industry. That is the claim of U.K. pharma industry group ABPI, which reported another small uptick in ...

Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry (ABPI) due to what the organisation describes as ‘serious breaches’ of its code of practice. The decision ...

UK pharmaceutical companies have historically relied upon consent as the lawful basis for the disclosure of healthcare professionals’ personal data relating to transfers of value. However, the low ...